The FDA has approved a pill called Zurzuvae, which is the world’s first medication for postpartum depression in the US. It is important for individuals to be aware of the guidelines and potential side effects before taking this oral medication. While pregnancy is often associated with mood swings and food cravings, postpartum depression is still a topic that requires more awareness. Many new mothers experience postpartum depression, but it often goes unnoticed due to lack of knowledge. The FDA’s approval of Zurzuvae provides a beneficial option for women dealing with severe postpartum depression. Postpartum depression is a major depressive episode that typically occurs after childbirth and can last for months or even years. Previous treatments for postpartum depression were limited to IV injections, but Zurzuvae offers a more accessible option. The medication is taken once a day for 14 days and comes with side effects such as drowsiness, dizziness, diarrhea, fatigue, colds, and urinary tract infections. Patients are advised not to drive or operate heavy machinery for at least 12 hours after taking the pill. While this approval is a step forward for mental health care, there is still a lack of awareness about postpartum depression in India. It is important to have conversations about this topic to help new mothers and raise awareness.
Everything You Should Know About Zurzuvae: The First Postpartum Depression Pill Approved in the US
Denial of responsibility! Swift Telecast is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – swifttelecast.com. The content will be deleted within 24 hours.